Great Lakes Advisors LLC lessened its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 2.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 42,226 shares of the company’s stock after selling 878 shares during the […]
First Trust Advisors LP trimmed its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 11.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 673,718 shares of the company’s stock after selling 91,049 shares during the quarter. First Trust Advisors […]
Impax Asset Management Group plc lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 16.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 175,000 shares of the company’s stock after purchasing an additional 25,000 shares during the period. Impax […]
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) – Equities researchers at HC Wainwright decreased their Q2 2023 EPS estimates for Neurocrine Biosciences in a report released on Thursday, May 4th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of $0.76 per share for the quarter, down from their prior estimate […]
Guggenheim upgraded shares of Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) from a neutral rating to a buy rating in a research report released on Thursday morning, The Fly reports. They currently have $145.00 target price on the stock. Other equities analysts have also recently issued reports about the company. Citigroup reduced their target price on […]